These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 34097573)

  • 1. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
    Johnson B; Cheng L; Koenitzer J; Catlett IM; Schafer P
    Front Immunol; 2024; 15():1437512. PubMed ID: 39403378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
    Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
    Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National and interprovincial prescribing patterns of JAK-inhibitors in Canada: a repeated cross-sectional analysis.
    Saunders KC; Shakeri A; Chu C; Drucker AM; Tadrous M
    Clin Rheumatol; 2024 Oct; 43(10):3083-3088. PubMed ID: 39198358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
    McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
    Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
    Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
    Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
    Harigai M; Honda S
    Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
    Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
    Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
    Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
    Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis.
    Covert LT; Prinz JA; Swain-Lenz D; Dvergsten J; Truskey GA
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI240-SI248. PubMed ID: 38317053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
    Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
    Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.